SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

SIGA Technologies, Inc.

SIGA develops medicines to prevent and treat emerging infectious diseases with high unmet medical needs. The company is focused on orthopoxviruses, including smallpox and mpox.

SIGA

SIGA Technologies | 3,321 followers on LinkedIn. SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly.

Antonio Rubens da Silva Filho

IT Leader with expertise in tech growth, transformation, and business development. Skilled in driving tech initiatives, team building & leadership…

Ed O.

Associate Director, Animal Studies, Poxvirus Research at SIGA Technologies Inc.

Andrew Russo

Senior Leader in Regulatory and Quality BioPharma

Kristin Murray

SIGA Technologies

We’re pleased to see continued focus on pandemic preparedness with the recent conclusion of The Pandemic Fund ’s second funding round. The Governing Board's commitment to granting resources aimed at enhancing prevention, preparedness, and response (PPR) capabilities across 50 countries is a vital step forward. At SIGA, we recognize the critical importance of PPR as we work to develop medicines to treat and prevent emerging #infectiousdiseases . By supporting initiatives that strengthen our collective capacity to detect, respond to, and prevent outbreaks, we are taking significant strides towards safeguarding #globalhealth .

#Infectiousdiseases pose a severe threat to #globalhealth that cannot be adequately addressed with vaccines alone. Among these, #smallpox , #mpox , and other orthopoxviruses stand out due to their high infectivity and lethality. Society must take proactive measures to prevent and mitigate outbreaks—whether they arise from natural occurrences, accidents, or intentional acts. At SIGA, we are dedicated to developing treatments to combat emerging infectious diseases with high unmet medical need, ensuring patients worldwide receive the care they need. Learn more: https://www.siga.com/

This #VeteransDay , we honor and express our heartfelt gratitude to the brave men and women who have served and continue to serve our country. We are proud to partner with the U.S. Department of Defense and provide our antiviral medicine to protect and support our military personnel. Ensuring the safety and well-being of our troops is essential, and we are committed to safeguarding those who serve.

Today we announced our third quarter 2024 financial results. Join our management team for a conference call and webcast at 4:30pm ET: https://lnkd.in/enPd4C-E

Today we announced that our management team will host a webcast and conference call to provide a business update at 4:30pm ET on November 7. See our press release: https://lnkd.in/eX52sZVg

Today we announced an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) with potential applications in a broad range of orthopoxviruses. Learn more in our press release: https://lnkd.in/ecd3xHyJ

Last week, our VP and Head of International Markets, Victor Gomes, MBA , had the privilege of attending the Health Emergency Preparedness and Response Authority (HERA) #InfoDay in Budapest. As we develop medicines to prevent and treat emerging #infectiousdiseases with high unmet medical needs, it was a pleasure to connect with global health leaders to exchange insights and discuss opportunities for collaboration between private sector, member states and health authorities for enhancing #healthsecurity . Thank you to EU in Emergencies and the European Commission for facilitating these important discussions!

Today we announced that we entered an agreement to supply our antiviral therapy in Morocco in response to a request from the Ministry of Health to help prepare and protect its citizens. We are proud to reaffirm our commitment to global #healthsecurity . See the full press release: https://lnkd.in/e9Wtrz6x

The escalating #mpox outbreak is raising alarms about a potential multi-country epidemic or even a new pandemic. This year alone, over 17,000 suspected cases have been reported across Africa, predominantly in the Democratic Republic of the Congo, underscoring the critical importance of a unified global response to combat the spread. In this JAMA publication, senior scholars from Johns Hopkins Center for Health Security examine the current global governance framework for a public health emergency of international concern (PHEIC), assess the mpox outbreak in Africa, and underscore the urgent need for countries to take swift action in response to this international call. See here: https://lnkd.in/enzvjjtf @Caitlin Rivers @Crystal Watson @Alexandra Phelan

Since the World Health Organization declared #mpox a public health emergency of international concern ( #PHEIC ) last month, two people traveling to Africa – one from Sweden and one from Thailand – have become infected with the clade Ib virus and brought it back to their home countries. As mpox spreads rapidly, Nature spoke with #infectiousdisease specialists to explore how this current emergency compares to the global outbreak of 2022 and how the clade Ib strain differs from the clade II strain that caused the earlier outbreak. Stay informed about the mpox outbreak and its impact on #publichealth : https://lnkd.in/gh4uM8jV

COM:SIGA

SIGA

Last Close

6.25

21/11 21:00

Market Cap

606.67M

Beta: -

Volume Today

322.78K

Avg: -

Financials Not Available